The fact that healthcare policy makers are shifting payment methods for medical services from a fee-for-service model to one based on care accountability could leave radiologists in an untenable position going forward, according to a viewpoint article published recently in the Journal of the American Medical Association.
A program to increase cancer screening rates in Canada by providing financial incentives to primary care physicians has had little effect on those screening rates, according to a study published in the July/August issue of the Annals of Family Medicine.
The Centers for Medicare & Medicaid Services (CMS) has proposed adding a claims-based quality reporting measure for colonoscopy to the Hospital Outpatient Quality Reporting (QPR) program.
How can radiology practices survive in midst of declining reimbursement figures?
The proposed rule for changes to the hospital outpatient prospective payment system (HOPPS) for 2015, recently released by the Centers for Medicare & Medicaid Services, would significantly increase breast biopsy payments.
The United States Preventive Services Task Force has finalized its draft recommendation against ultrasound carotid artery stenosis screening as a way of preventing stroke.
The Centers for Medicare and Medicaid Services (CMS) has released the 2015 Medicare Physician Fee Schedule proposed rule and like the healthcare community as a whole, as reported by FierceHealthcare, it provides somewhat of a mixed bag for radiology.
Attempting to make good, informed decisions on these kinds of issues is next to impossible without good data, according to Atlanta-based radiologist Richard Woodcock.
In an opinion article published last week, Renda Soylemez Wiener, M.D., of Boston University, wrote that despite the concerns expressed by MEDCAC, "there are reasons to believe that LDCT screening can be implemented safely and effectively" within the Medicare community.
Despite the refusal of the Centers for Medicare & Medicaid Services to provide full coverage of amyloid PET imaging, radiopharmaceutical companies continue research efforts in the field of Alzheimer's disease and other disorders like Parkinson's disease.